Bilthoven Biologicals
Bilthoven Biologicals is a leading vaccine manufacturer dedicated to producing high-quality vaccines to meet global demand and contribute to the eradication of life-threatening diseases such as polio. Originating from the Dutch Vaccine Institute and now part of the Cyrus Poonawalla Group, BBio emphasizes quality, responsibility, and collaboration with partners worldwide. The company operates state-of-the-art facilities, including a GMP manufacturing plant, and is actively involved in pandemic preparedness, vaccine innovation, and strategic collaborations to enhance global health security.
Industries
Nr. of Employees
medium (51-250)
Bilthoven Biologicals
Products
Bacillus Calmette–Guérin (BCG) vaccine
Live attenuated bacterial vaccine produced for tuberculosis prevention and supplied for public-health immunization programs.
Tetanus vaccine
Vaccine produced for the prevention of tetanus suitable for routine immunization and campaigns.
DTP combination vaccine
Combination vaccine for diphtheria, tetanus and pertussis intended for routine childhood immunization.
Inactivated poliovirus vaccine (IPV)
Inactivated poliovirus vaccine manufactured at scale for global immunization and eradication programs.
Vaccine used in treatment of bladder cancer (manufactured/contract-manufactured)
Vaccines used as part of a cancer treatment regimen (bladder cancer) manufactured or contract-manufactured at the facility for supply to the European market.
Bacillus Calmette–Guérin (BCG) vaccine
Live attenuated bacterial vaccine produced for tuberculosis prevention and supplied for public-health immunization programs.
Tetanus vaccine
Vaccine produced for the prevention of tetanus suitable for routine immunization and campaigns.
DTP combination vaccine
Combination vaccine for diphtheria, tetanus and pertussis intended for routine childhood immunization.
Inactivated poliovirus vaccine (IPV)
Inactivated poliovirus vaccine manufactured at scale for global immunization and eradication programs.
Vaccine used in treatment of bladder cancer (manufactured/contract-manufactured)
Vaccines used as part of a cancer treatment regimen (bladder cancer) manufactured or contract-manufactured at the facility for supply to the European market.
Services
cGMP contract manufacturing for viral and bacterial vaccines and viral vectors, supporting clinical and commercial production and global supply agreements.
Provision of GMP-ready manufacturing space and partnership arrangements (facility leasing) to enable third-party production of viral vaccines and vectors.
On-site QC laboratory services including batch testing for safety, identity and potency plus routine environmental and microbiological monitoring of production areas.
cGMP contract manufacturing for viral and bacterial vaccines and viral vectors, supporting clinical and commercial production and global supply agreements.
Provision of GMP-ready manufacturing space and partnership arrangements (facility leasing) to enable third-party production of viral vaccines and vectors.
On-site QC laboratory services including batch testing for safety, identity and potency plus routine environmental and microbiological monitoring of production areas.
Expertise Areas
- GMP vaccine and viral vector manufacturing
- Aseptic formulation, fill and finish
- Quality control microbiology and environmental monitoring
- Quality assurance, deviation handling and CAPA
Key Technologies
- Stirred-tank bioreactor fermentation
- Bioreactor scale-up to large volumes (~1,200 L)
- cGMP viral vector and viral vaccine manufacturing
- Aseptic fill-and-finish systems
News & Updates
BBio welcomed the EU delegation led by Mr. Muschel, Director of Health Emergency Preparedness (HERA).
Jurgen Kwik has been appointed as the new CEO of BBio, bringing extensive experience in the life sciences sector.
A detailed report on BBio's efforts in pandemic preparedness, featured in NRC.
BBio has supplied over 150 million doses of IPV to 129 countries, aiding in the global eradication of polio.
Polio eradication milestone in Africa
Africa was declared polio-free on August 25, 2020, with BBio contributing to this achievement.
Increased IPV production capacity
Between 2012 and 2020, BBio increased its annual IPV production capacity tenfold.
BBio welcomed the EU delegation led by Mr. Muschel, Director of Health Emergency Preparedness (HERA).
Jurgen Kwik has been appointed as the new CEO of BBio, bringing extensive experience in the life sciences sector.
A detailed report on BBio's efforts in pandemic preparedness, featured in NRC.
BBio has supplied over 150 million doses of IPV to 129 countries, aiding in the global eradication of polio.
Polio eradication milestone in Africa
Africa was declared polio-free on August 25, 2020, with BBio contributing to this achievement.
Increased IPV production capacity
Between 2012 and 2020, BBio increased its annual IPV production capacity tenfold.